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Journal of Hepatology 20group of heterozygous or homozygous subjects for the major
allele (p = 0.02 for ALT and p = 0.01 for steatosis). Moreover, after
weight loss, no differences among PNPLA3 genotypes were found
in ALT levels or in the prevalence of steatosis (p = 0.1 and p = 0.2,
respectively).
Both the relationships between DBMI SDS and DALT and
between DW/Hr and DALT were analysed, based on the different
PNPLA3 genotypes, and the slope of the relative regression lines
were compared (Fig. 1).
Homozygous children for the PNPLA3 minor allele (148M)
showed a stronger correlation between DALT and DW/Hr than
those carrying the other genotypes, as we observed in the com-
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Fig. 1. Correlations between ALT levels reduction (DALT) and waist circum-
ference to height ratio, W/Hr (DW/Hr) or BMI SDS (DBMI SDS) decrease
according to PNPLA3 genotypes in a group of 129 obese children subjected to
a weight loss program. (A) Regression analysis describing the relationship
between ALT levels reduction (DLT) and W/Hr reduction (DW/Hr) in patients
homozygous for PNPLA3 148M variant and in patients carrying the PNPLA3 148I
variant. The regression between DALT and DW/Hr in the group of patients
homozygous for PNPLA3 148M variant is described by the equation y = 0.29 +
169.4  x (r = 0.40; p = 0.004). The equation for PNPLA3 I/M and I/I was y = 5.0 +
32.6  x (r = 0.12; p = 0.2). The comparison between the slope of the two regression
lines is signiﬁcant (p = 0.002). (B) Regression analysis describing the relationship
between ALT levels redution (DALT) and BMI SDS decrease (DBMI SDS) in patients
homozygous for PNPLA3 148M variant and in patients carrying the PNPLA3 184I
variant. The regression between DALT and DBMI SDS in the group of patients
homozygous for PNPLA3 148M variant is described by the equation y = 8.706 +
5.16  x (r = 0.07; p = 0.73). The equation for PNPLA3 I/M and I/I was y = 5.86 +
1.54  x (r = 0.05;p = 0.57). The comparisonbetween the slopeof the two regression
lines is not signiﬁcant (p = 0.38). (This ﬁgure appears in colour on the web.)To the Editor:
In the patatin-like phospholipase domain-containing 3 gene
(PNPLA3), there is a polymorphism named rs738409, which
encodes for the adiponutrin I148M variant and is a genetic deter-
minant of liver fat and non-alcoholic fatty liver disease (NAFLD)
Many works support the correlation among the PNPLA3
rs738409 polymorphism, ALT serum levels and hepatic steatosis
A recent study has demonstrated that this variant is associated
with increased levels of liver enzymes and with liver steatosis
in obese children and adolescents, suggesting that it confers
genetic susceptibility to liver damage from a young age [1].
We have shown that in obese children, the magnitude of the
association of PNPLA3 with liver enzymes is driven by the size
of abdominal fat expressed as waist to height ratio (W/Hr) and
we stratiﬁed the individual risk of developing liver damage on
the basis of the interaction between the PNPLA3 genotypes and
waist circumference [2]. Furthermore, the interplay between vis-
ceral fat and PNPLA3 in producing liver damage has recently been
conﬁrmed in adults [3] and patients with chronic hepatitis C [4]
In addition to PNPLA3, a number of predisposing genetic poly-
morphisms have been associated with NAFLD [5]. In order to dis-
sect the interaction between abdominal fat and PNPLA3, we
studied 129 obese children before and after a weight loss
program.
The frequency of the distribution of the different PNPLA3
rs738409 genotypes was in Hardy-Weinberg equilibrium
(p >0.05).
Fifty-three patients were homozygous for the wild type allele
(CC) while 51 were heterozygous (CG) and 25 were homozygous
for the minor allele (GG).
The frequency of the PNPLA3 minor allele (148M) was 0.30
which is in line with the frequencies reported in obese subjects
belonging to the same geographic area [1].
By analysing the children on the basis of their PNPLA3 geno-
types, we observed that before the weight loss program, ALT
and AST levels in the serum increased signiﬁcantly in the children
carrying the 148M allele (p = 0.01 and p = 0.02, respectively)
adjusting for age, gender, pubertal stage, and BMI-SDS. Of
148M homozygotes, 24% had ALT levels above 40 IU/L compared
to 16% of heterozygous and 9% of homozygous for the 148I major
allele (p = 0.02). The prevalence of steatosis was also different
according to the PNPLA3 genotypes, with 17% of obese children
148I homozygotes showing steatosis, 33% of heterozygotes and
76% of 148M homozygotes (p = 0.01), adjusting for age, gender
pubertal stage, and BMI-SDS.
After weight loss, all children reduced their BMI SDS by at
least 0.5. Reduction in BMI SDS and W/Hr were not statistically
different among PNPLA3 genotypes.
The group of homozygous subjects for the minor allele (148M)
presented a greater reduction in serum ALT concentrations
(DALT) and in the prevalence of steatosis compared with the
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ison performed for DBMI SDS was not signiﬁcant (p = 0.38)
(Fig. 1B). These results support the idea that it is the abdominal
fat (as expressed by W/Hr) more than the overall adiposity
(expressed by BMI), the external (not genetic) factor which mod-
ulates the effect of PNPLA3 148M allele on liver damage.
Exploring whether the PNPLA3 148M allele inﬂuences the abil-
ity of weight loss to decrease liver fat, Sevastianova et al. [6] inves-
tigated 18 subjects placed on a hypocaloric low-carbohydrate diet
for 6 days and demonstrated that weight loss is an effectiveway to
decrease liver fat, irrespective of the PNPLA3 genotype. Indeed,
short termweight loss decreases liver fat contentmore in homozy-
gous carriers of PNPLA3 148Mallele than in those carrying the 148I
allele. These results are in agreement with our data.
The mutant PNPLA3 148M allele is partially unable to hydro-
lyse intra-hepatocytic triglycerides [7,8], which increases the risk
of liver steatosis. Studies have also shown that there is about a
three-fold increase of PNPLA3 expression in obese human sub-
jects after the completion of a weight loss program [9]. It is pos-
sible, therefore, that the interaction between adiposity and
PNPLA3 may well be modulated by the effect of adipose tissue
changes on PNPLA3 expression.
An important clinical implication of the present study is that
obese children with fat liver carrying the PNPLA3 148M allele
are the patients who would most beneﬁt from weight loss.
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Uncovering the molecular events associated with increased intestinal
permeability in liver cirrhosis: The pivotal role of enterocyte tight
junctions and future perspectives
To the Editor:
We read with great interest the recently published research study
by Dr. Du Plessis and colleagues on the role of intestinal
macrophages in intestinal epithelial barrier dysfunction and
hyperpermeability in patients with cirrhosis [1]. The authors
demonstrated that decompensated liver cirrhosis was associated
with the presence of signiﬁcantly higher numbers of activated
intestinal macrophages (CD33+/CD14+/Trem-1+) expressing iNOS
and secretingNO and IL-6, in conjunctionwith increased duodenal
paracellular permeability and increased expression of the tight
junction (TJ) protein Claudin-2. They speculated that activation
of intestinalmacrophagesmight represent an importantmolecular
event implicated in the disruption of the intestinal epithelial
barrier in cirrhosis through secretion of TJ-regulating factors such
as NO and IL-6.
Despite the indisputable important pathophysiological role of
gut permeability alterations in the development of complications
of cirrhosis from diverse organs, little is known of its underlying
molecular and/or cellular mechanisms and relevant evidence
comes from extrapolation of data from animal studies. However,
animalmodels can never reproduce human diseases to the desired
level. Therefore, it is very positive that recent efforts focus on clin-
ical studies dealingwith this emerging concept; such studiesmight
endow us with a better understanding of the pathogenetic mecha-
nisms in humans. Our research group has recently shown, for the
ﬁrst time in humans, that altered expression of key structural
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